Which multiple sclerosis DMTs would you consider in patients with concurrent Crohn's disease and elevated JCV Ab titers?

This may depend on the course/activity of both the MS and Chron's. S1P inhibitors, specifically ozanimod, have minimal risk of PML and are FDA-approved for both UC/Crohn's and MS. While the treatment landscape continues to shift, S1P inhibitors are generally considered either moderate or high-effica...